peginterferon beta-1a vs Rebif (interferon beta 1a)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline

peginterferon beta-1a · Plegridy

Marketed by Biogen

Approved in Multiple Sclerosisbiologic
Reliable signal

NCT00906399 · Phase 3 · completed

This was a large, randomized, triple-blind, placebo-controlled trial with 1,516 participants. Its primary clinical endpoint, annualized relapse rate at one year, was statistically significantly lower with both peginterferon beta-1a schedules than with placebo (p=0.0007 for every 2 weeks and p=0.0114 for every 4 weeks).

Next expected readout: May 2027 · NCT03958877 (registry estimate)

Reported efficacy

Annualized Relapse Rate (ARR) at 1 Year: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481) (met)

Result source: NCT00906399

Rebif (interferon beta 1a)

Marketed by Merck KGaA and partners

Approved in Multiple Sclerosisbiologic (interferon)
Weak signal

NCT00110396 · Phase 3 · completed

The study was a single-group, open-label trial without randomization or a placebo or active comparator. Its primary endpoint was a laboratory antibody measure rather than a clinical outcome; 45 of 259 assessed participants were neutralising-antibody positive at week 96, but the design did not provide a controlled comparison.

Reported efficacy

Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Rebif New Formulation (RNF) Cohort 45 participants (not_applicable)

Result source: NCT00110396

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointpeginterferon beta-1aRebif (interferon beta 1a)
Annualised relapse rate0.3 vs 0.4−0.1 vs placeboevery 4 weeks · wk 52 · n 500NCT00906399
2 other results
  • 0.3 vs 0.4 every 2 weeks · wk 52 · n 512 · Phase 3 · primary NCT00906399
  • 0 vs 0.5 125 µg · wk 96 · n 6 · Phase 3 · secondary NCT03870763
—Not posted · NCT00735007
Free of 3-month confirmed disability progression (%)—Trial running · NCT03958877—Not posted · NCT00735007
New or enlarging T2 lesions7.9 vs 10.9−3 vs placeboevery 4 weeks · wk 52 · n 462NCT00906399
1 other result
  • 3.6 vs 10.9 every 2 weeks · wk 52 · n 457 · Phase 3 · secondary NCT00906399
—Not posted · NCT00735007

Annualised relapse rate

peginterferon beta-1a
0.3 vs 0.4−0.1 vs placeboevery 4 weeks · wk 52 · n 500NCT00906399
2 other results
  • 0.3 vs 0.4 every 2 weeks · wk 52 · n 512 · Phase 3 · primary NCT00906399
  • 0 vs 0.5 125 µg · wk 96 · n 6 · Phase 3 · secondary NCT03870763
Rebif (interferon beta 1a)
—Not posted · NCT00735007

Free of 3-month confirmed disability progression (%)

peginterferon beta-1a
—Trial running · NCT03958877
Rebif (interferon beta 1a)
—Not posted · NCT00735007

New or enlarging T2 lesions

peginterferon beta-1a
7.9 vs 10.9−3 vs placeboevery 4 weeks · wk 52 · n 462NCT00906399
1 other result
  • 3.6 vs 10.9 every 2 weeks · wk 52 · n 457 · Phase 3 · secondary NCT00906399
Rebif (interferon beta 1a)
—Not posted · NCT00735007
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. peginterferon beta-1a: 5 of 5 rows · Rebif (interferon beta 1a): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricpeginterferon beta-1aRebif (interferon beta 1a)
Time to First Relapse
time to event · months
NA vs 5.47 placebo months @ 96wk125 µga,b,c,d
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
6.34 vs 4.06 Rebif months @ 52wk*a,b,c,d
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to months from 193 days as posted
Dropout rate
14.8%every 2 weekse
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
12.6%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
50%125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
18.4%BIIB017 Plus Current FLS Therapy
NCT01939002 · Phase 3 · combination
18.4%BIIB017 Plus Naproxen
NCT01939002 · Phase 3 · combination
22.3%Q2W
NCT01332019 · Phase 3 · monotherapy
21.3%Q4W
NCT01332019 · Phase 3 · monotherapy
14%125 μg
NCT02587065 · Phase 4 · registry result, not featured evidence
13.8%e
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
—Non-Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
—Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
13.8%
NCT00428584 · Phase 3 · registry result, not featured evidence
24.5%
NCT02727907 · Phase 2/3 · registry result, not featured evidence
4.4%
NCT01071083 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.7%every 2 weekse
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
4.4%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
12.6%BIIB017 Plus Current FLS Therapy
NCT01939002 · Phase 3 · combination
13.3%BIIB017 Plus Naproxen
NCT01939002 · Phase 3 · combination
4%Q2W
NCT01332019 · Phase 3 · monotherapy
2.5%Q4W
NCT01332019 · Phase 3 · monotherapy
7.3%125 μg
NCT02587065 · Phase 4 · registry result, not featured evidence
5.8%e
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
—Non-Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
—Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
—
NCT00428584 · Phase 3 · registry result, not featured evidence
—
NCT02727907 · Phase 2/3 · registry result, not featured evidence
0%
NCT01071083 · Phase 2 · registry result, not featured evidence
Serious AEs
10.7%every 2 weekse
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
14%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
8.9%every 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
15.3%every 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0%125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
3.9%BIIB017 Plus Current FLS Therapy
NCT01939002 · Phase 3 · combination
6.1%BIIB017 Plus Naproxen
NCT01939002 · Phase 3 · combination
16.6%Q2W
NCT01332019 · Phase 3 · monotherapy
21.6%Q4W
NCT01332019 · Phase 3 · monotherapy
0%125 μg
NCT02587065 · Phase 4 · registry result, not featured evidence
5.8%e
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
8.5%Non-Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
5.3%Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
6.2%
NCT00428584 · Phase 3 · registry result, not featured evidence
0%
NCT02727907 · Phase 2/3 · registry result, not featured evidence
—
NCT01071083 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
every 2 weekse
injection site erythema 61.4% (placebo 6.6%)
influenza like illness 46.4% (placebo 12.6%)
pyrexia 44.2% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 9 more results
every 4 weeks
injection site erythema 56.4% (placebo 6.6%)
influenza like illness 46.8% (placebo 12.6%)
pyrexia 43.6% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
every 2 weeks
injection site erythema 48.4% (placebo 6.6%)
influenza like illness 43.8% (placebo 12.6%)
pyrexia 31.1% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
every 4 weeks
injection site erythema 48.1% (placebo 6.6%)
influenza like illness 45.3% (placebo 12.6%)
pyrexia 31.4% (placebo 15%)
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
125 µg
headache 66.7% (placebo 33.3%)
abdominal pain 33.3% (placebo 0%)
anxiety 16.7% (placebo 0%)
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
injection site erythema 44.7%
injection site reaction 22.3%
injection site pruritus 11.7%
NCT01939002 · Phase 3 · combination
injection site erythema 34.7%
injection site reaction 21.4%
influenza like illness 13.3%
NCT01939002 · Phase 3 · combination
Q2W
influenza like illness 42.8%
injection site erythema 41%
headache 29.4%
NCT01332019 · Phase 3 · monotherapy
Q4W
influenza like illness 44.2%
injection site erythema 42%
multiple sclerosis relapse 29.3%
NCT01332019 · Phase 3 · monotherapy
125 μg
influenza like illness 14.5%
injection site reactions 5.2%
pyrexia 5.2%
NCT02587065 · Phase 4 · registry result, not featured evidence
e
influenza like illness 67.7%
headache 37.7%
injection site erythema 24.2%
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
headache 32.2%
pain 16.9%
myalgia 11%
NCT00472797 · Phase 3 · registry result, not featured evidence
headache 24.8%
pain 14.2%
influenza-like illness 8%
NCT00472797 · Phase 3 · registry result, not featured evidence
general disorders and administration site condition 67.7%
infections and infestations 58.5%
nervous system disorders 44.6%
NCT00428584 · Phase 3 · registry result, not featured evidence
flu-like syndrom 28.3%
local reaction 28.3%
neutropenia 20.8%
NCT02727907 · Phase 2/3 · registry result, not featured evidence
nasopharyngitis 24.4% (placebo 11.9%)
headache 17.8% (placebo 7.1%)
dizziness 6.7% (placebo 0%)
NCT01071083 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2/3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 96 weeks versus 52 weeks.
  5. ePopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

peginterferon beta-1a

Annualized Relapse 0 vs 0.46 placebo per year @ 96wk125 µg
event rate · per year
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 2 more results
0.288 vs 0.397 placebo per year @ 52wkevery 4 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.256 vs 0.397 placebo per year @ 52wkevery 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
New or Enlarging T2 Lesion 7.9 vs 10.9 placebo lesions @ 52wkevery 4 weeks
event count · lesions
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
3.6 vs 10.9 placebo lesions @ 52wkevery 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Proportion Relapsed 0.222% (n=500) vs 0.291% (n=500) placebo @ 52wkevery 4 weeks
responder rate · % of participants
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.187% (n=512) vs 0.291% (n=500) placebo @ 52wkevery 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Sustained Disability Progression 0.068 vs 0.105 placebo ratio @ 52wkevery 4 weeks
event count · ratio
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.068 vs 0.105 placebo ratio @ 52wkevery 2 weeks
NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
New or Newly Enlarging T2 Lesion 1 vs 3.3 placebo count @ 48wk125 µg
event count · count
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
1.3 vs 3.5 placebo count @ 96wk125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Gd-enhancing Lesion 0 vs 1.5 placebo count @ 48wk125 µg
event count · count
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.25 vs 0.5 placebo count @ 96wk125 µg
NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Annualized Relapse 0.189 per yearQ4W
event rate · per year
No placebo or comparator arm
NCT01332019 · Phase 3 · monotherapy
show 1 more result
0.142 per yearQ2W
NCT01332019 · Phase 3 · monotherapy
Relapse 29% (n=529)Q4W
responder rate · % of participants
No placebo or comparator arm
Relapsed
NCT01332019 · Phase 3 · monotherapy
show 1 more result
23% (n=547)Q2W
Relapsed
NCT01332019 · Phase 3 · monotherapy
New or Enlarging T2 Lesion 4.4 lesions @ 48wkQ4W
event count · lesions
No placebo or comparator arm
NCT01332019 · Phase 3 · monotherapy
show 3 more results
1.9 lesions @ 48wkQ2W
NCT01332019 · Phase 3 · monotherapy
8.9 lesions @ 96wkQ4W
NCT01332019 · Phase 3 · monotherapy
3.9 lesions @ 96wkQ2W
NCT01332019 · Phase 3 · monotherapy
New Active Lesion 4.4 lesions @ 48wkQ4W
event count · lesions
No placebo or comparator arm
NCT01332019 · Phase 3 · monotherapy
show 3 more results
2 lesions @ 48wkQ2W
NCT01332019 · Phase 3 · monotherapy
9 lesions @ 96wkQ4W
NCT01332019 · Phase 3 · monotherapy
3.9 lesions @ 96wkQ2W
NCT01332019 · Phase 3 · monotherapy
New T1 Hypointense Lesion 1.4 lesions @ 49wkQ4W
event count · lesions
No placebo or comparator arm
NCT01332019 · Phase 3 · monotherapy
show 3 more results
0.8 lesions @ 49wkQ2W
NCT01332019 · Phase 3 · monotherapy
2.8 lesions @ 96wkQ4W
NCT01332019 · Phase 3 · monotherapy
1.5 lesions @ 96wkQ2W
NCT01332019 · Phase 3 · monotherapy
Gadolinium Enhancing Lesion 0.7 lesions @ 48wkQ4W
event count · lesions
No placebo or comparator arm
Week 48; n=481, 493
NCT01332019 · Phase 3 · monotherapy
show 1 more result
0.2 lesions @ 48wkQ2W
Week 48; n=481, 493
NCT01332019 · Phase 3 · monotherapy

+ 60 further endpoints in the CSV export.

Rebif (interferon beta 1a)

Pain VAS 0.67 vs 1.14 Betaseron mm
absolute change · mm
Mean Change to 30 Minutes Post-Injection
NCT00428584 · Phase 3 · registry result, not featured evidence
Pain VAS 1.46 vs 4.63 Betaseron mm
absolute change · mm
NCT00428584 · Phase 3 · registry result, not featured evidence
show 1 more result
0.7 vs 1.89 Betaseron mm
NCT00428584 · Phase 3 · registry result, not featured evidence
Pain VAS 1.67 mm
absolute change · mm
Extension (open-label)
No placebo or comparator arm
NCT00428584 · Phase 3 · registry result, not featured evidence
show 2 more results
0.4 mm
NCT00428584 · Phase 3 · registry result, not featured evidence
0.34 mm
NCT00428584 · Phase 3 · registry result, not featured evidence
Newly Active Lesions 0 vs 0 Rebif lesions @ 52wk
event count · lesions
NCT02727907 · Phase 2/3 · registry result, not featured evidence
show 1 more result
0 vs 1 placebo lesions @ 16wk
NCT02727907 · Phase 2/3 · registry result, not featured evidence
Annualized Relapse 0.113 relapses @ 52wk
event rate · relapses
No placebo or comparator arm
NCT02727907 · Phase 2/3 · registry result, not featured evidence
Relapse Free 92.5% (n=53) vs 88.2% (n=51) placebo @ 16wk
event count · % of participants
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to % from 49 Count of Participants as posted
show 1 more result
77.4% (n=53) vs 76.5% (n=51) placebo @ 52wk*
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to % from 41 Count of Participants as posted
Time to First Relapse 6.8 months @ 96wk
time to event · months
No placebo or comparator arm
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to months from 207 days as posted
Newly Active Lesions 0 lesions @ 96wk
event count · lesions
No placebo or comparator arm
NCT02727907 · Phase 2/3 · registry result, not featured evidence
Annualized Relapse 0.208 vs 0.145 Rebif relapses @ 96wk
event rate · relapses
NCT02727907 · Phase 2/3 · registry result, not featured evidence
MRI and or Clinical Relapse Rescue 4.7% (n=45) vs 60.5% (n=41) placebo @ 28wk
absolute value · percentage points
NCT01071083 · Phase 2 · registry result, not featured evidence
MRI Activity Rescue 0% (n=45) vs 52.5% (n=41) placebo @ 28wk
absolute value · percentage points
NCT01071083 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: peginterferon beta-1a's landscape · Rebif (interferon beta 1a)'s landscape